Source: https://www.global-regulation.com/law/australia/227349/national-health-%2528efficient-funding-of-chemotherapy%2529-special-arrangement-amendment-instrument-2013-%2528no.-9%2529-%2528no.-pb-64-of-2013%2529.html
Timestamp: 2017-11-19 17:37:25
Document Index: 641091208

Matched Legal Cases: ['art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1', 'art 1']

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2013 (No. 9) (No. PB 64 of 2013) (Australia)
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2013 (No. 9) (No. PB 64 of 2013)
Link to law: https://www.comlaw.gov.au/Details/F2013L01735
PB 64 of 2013
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2013 (No. 9)
I, Steve Dunlop, Acting Assistant Secretary, Pharmaceutical Access Branch, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health and Medical Research, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
(1) This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2013 (No.9).
(2) This Instrument may also be cited as PB 64 of 2013.
Schedule 1 Part 1 entry for Bleomycin in the form Powder for injection containing bleomycin sulfate 15,000 I.U. and brand Bleo 15K:
omit from the column headed “Responsible Person”: WQ substitute: GN
Schedule 1 Part 1 entry for Carboplatin in each of the forms: Solution for I.V. injection 150 mg in 15 mL; Solution for I.V. injection 450 mg in 45 mL; and Solution for I.V. injection 50 mg in 5 mL and brand Carbaccord:
Schedule 1 Part 1 entry for Doxorubicin in the form Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 10 mg in 5 ml single dose vial and brand Accord Doxorubicin:
Schedule 1 Part 1 entry for Doxorubicin in the form Solution for I.V. injection or intravesical administration containing doxorubicin hydrochloride 200 mg in 100 ml single dose vial and brand Accord Doxorubicin:
Schedule 1 Part 1 entry for Epirubicin in the form Solution for injection containing epirubicin hydrochloride 10 mg in 5 mL and brand Epiccord:
Schedule 1 Part 1 entry for Epirubicin in each of the forms: Solution for injection containing epirubicin hydrochloride 20 mg in 10 mL; Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL; and Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL and brand Epiccord:
Schedule 1 Part 1 entry for Fludarabine in the form Powder for I.V. injection containing fludarabine phosphate 50 mg and brand Farine:
Schedule 1 Part 1, entry for Gemcitabine in the form Powder for I.V. infusion 1 g (as hydrochloride) with manner of administration Injection:
AS‑Gemcitabine
(b) omit from the column headed “Responsible Person” for the brand “Gemaccord”: WQ substitute: GN
(c) omit from the column headed “Responsible Person” for the brand “Gemcitabine Actavis”:WQ substitute: GN
(d) omit from the column headed “Responsible Person” for the brand “Gemplan”: WQ substitute: GN
Schedule 1 Part 1, entry for Gemcitabine in the form Powder for I.V. infusion 2 g (as hydrochloride) with manner of administration Injection:
(b) omit from the column headed “Responsible Person” for the brand “Gemcitabine Actavis 2000”: WQ substitute: GN
Schedule 1 Part 1, after entry for Gemcitabine in the form Powder for I.V. infusion 200 mg (as hydrochloride) with manner of administration Injection:
(c) omit from the column headed “Responsible Person” for the brand “Gemcitabine Actavis”: WQ substitute: GN
Schedule 1 Part 1, entry for Irinotecan in the form I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL:
(a) omit from the column headed “Responsible Person” for the brand “Irinoccord”: WQ substitute: GN
(b) omit from the column headed “Responsible Person” for the brand “Tecan”: WQ substitute: GN
Schedule 1 Part 1, entry for Irinotecan in the form I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL:
(a) omit from the column headed “Responsible Person” for the brand “Irinoccord”:WQ substitute: GN
Schedule 1 Part 1, entry for Irinotecan in the form I.V. injection containing irinotecan hydrochloride trihydrate 500 mg in 25 mL:
omit from the column headed “Responsible Person” for the brand “Tecan”: WQ substitute: GN
Schedule 1 Part 1 entry for Methotrexate in each of the forms: Injection 50 mg in 2 mL vial; Solution concentrate for I.V. infusion 1000 mg in 10 mL vial and brand Methaccord:
Schedule 1 Part 1 entry for Oxaliplatin in each of the forms: Powder for I.V. infusion 100 mg; Powder for I.V. infusion 50 mg and brand Xalox:
Schedule 1 Part 1, entry for Oxaliplatin in the form Solution concentrate for I.V. infusion 100 mg in 20 mL with manner of administration Injection:
AS‑Oxaliplatin
(b) omit from the column headed “Responsible Person” for the brand “Oxaliccord”: WQ substitute: GN
Schedule 1 Part 1, entry for Oxaliplatin in the form Solution concentrate for I.V. infusion 200 mg in 40 mL with manner of administration Injection:
Schedule 1 Part 1, entry for Oxaliplatin in the form Solution concentrate for I.V. infusion 50 mg in 10 mL with manner of administration Injection:
Schedule 1 Part 1, entry for Paclitaxel in the form Solution concentrate for I.V. infusion 100 mg in 16.7 mL with manner of administration Injection:
GN‑Paclitaxel
(b) omit from the column headed “Responsible Person” for the brand “Plaxel”: WQ substitute: GN
Schedule 1 Part 1, entry for Paclitaxel in the form Solution concentrate for I.V. infusion 150 mg in 25 mL and brand Plaxel
omit from the column headed “Responsible Person: WQ substitute: GN
Schedule 1 Part 1, entry for Paclitaxel in the form Solution concentrate for I.V. infusion 30 mg in 5 mL with manner of administration Injection:
Schedule 1 Part 1, entry for Paclitaxel in the form Solution concentrate for I.V. infusion 300 mg in 50 mL with manner of administration Injection:
Schedule 1 Part 1, entry for Vinorelbine in the form Solution concentrate for I.V. infusion 10 mg (as tartrate) in 1 mL with manner of administration Injection:
AS‑Vinorelbine
Schedule 1 Part 1, entry for Vinorelbine in the form Solution concentrate for I.V. infusion 50 mg (as tartrate) in 5 mL with manner of administration Injection:
[25] Schedule 2, entry for Ondansetron in the form Tablet (orally disintegrating) 4 mg and brand Onsetron ODT 4:
[26] Schedule 2, entry for Ondansetron in the form Tablet (orally disintegrating) 8 mg and brand Onsetron ODT 8:
[27] Schedule 3, after the entry for the code GK:
[28] Schedule 3, after the entry for TX: